Cargando…

Reduced FEV(1) as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors

BACKGROUND: The aim of study is to investigate the influence of pulmonary function on the prognosis in patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI). PATIENTS AND METHODS: Data were collected retrospectively from 151 patients with stage IV NSC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Yi-Luen, Shen, Chia-I, Chiang, Chi-Lu, Huang, Hsu-Ching, Chou, Kun-Ta, Chiu, Chao-Hua, Chen, Yuh-Min, Luo, Yung-Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980716/ https://www.ncbi.nlm.nih.gov/pubmed/35391883 http://dx.doi.org/10.3389/fmed.2022.860733

Ejemplares similares

Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer
por: Shen, Chia-I, et al.
Publicado: (2021)

Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell‐free DNA from non‐small‐cell lung cancer patients with leptomeningeal metastases
por: Chiang, Chi‐Lu, et al.
Publicado: (2023)

Fixed Cut-Off for FEV1/FEV6 and FEV6 in Detection of Obstructive and Restrictive Patterns
por: Aghili, Rokhsareh, et al.
Publicado: (2013)

Reliability of FEV(1)/FEV(6) to Diagnose Airflow Obstruction Compared with FEV(1)/FVC: The PLATINO Longitudinal Study
por: Perez-Padilla, Rogelio, et al.
Publicado: (2013)

Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer
por: Shen, Chia-I, et al.
Publicado: (2022)

Bronchodilator Response of FEV6 and FEV3 as Surrogates of Forced Vital Capacity
por: Mehrparvar, Amir Houshang, et al.
Publicado: (2014)

Genome organization and molecular characterization of the three Formica exsecta viruses—FeV1, FeV2 and FeV4
por: Dhaygude, Kishor, et al.
Publicado: (2019)

Cut-off value of FEV(1)/FEV(6) as a surrogate for FEV(1)/FVC for detecting airway obstruction in a Korean population
por: Chung, Kyung Soo, et al.
Publicado: (2016)

Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiation
por: Shukla, Nikhil A, et al.
Publicado: (2020)

The Tri-iodothyronine (T3) Level Is a Prognostic Factor for Patients With Advanced NSCLC: Receiving Immune Checkpoint Inhibitors and Is Associated With Liver Metastasis
por: Kim, Yoonjoo, et al.
Publicado: (2022)

Utility of FEV(1)/FEV(6) index in patients with multimorbidity hospitalized for decompensation of chronic diseases
por: Komal, Shakeel, et al.
Publicado: (2019)

The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy
por: Tsai, Tsung-Han, et al.
Publicado: (2023)

Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy
por: Huang, Pei‐Wei, et al.
Publicado: (2019)

Progressive Pleural Effusion as an Immune-Related Adverse Event in NSCLC: A Case Report
por: Shen, Chia-I, et al.
Publicado: (2021)

Liver-specific metastases as an independent prognostic factor in cancer patients receiving hospice care in hospital
por: Huang, Kun-Siang, et al.
Publicado: (2023)

Forced Expiratory Volume in 6 s (FEV(6)) and FEV(1)/FEV(6) Values as a Viable Alternative for Forced Vital Capacity (FVC) and FEV(1)/FVC Values During Pregnancy in South East Nigeria: A Preliminary Study
por: Nwagha, U, et al.
Publicado: (2014)

State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan
por: Luo, Yung-Hung, et al.
Publicado: (2022)

Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment
por: Chou, Wen-Chi, et al.
Publicado: (2013)

Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy
por: Shen, Ying-Chun, et al.
Publicado: (2021)

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
por: Wu, Chiao-En, et al.
Publicado: (2020)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Correction: Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment
por: Chou, Wen-Chi, et al.
Publicado: (2013)

Allergen bronchoprovocation: correlation between FEV(1) maximal percent fall and area under the FEV(1) curve and impact of allergen on recovery
por: Durr, Sarah-Marie, et al.
Publicado: (2023)

Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancer
por: Guo, Jhe‐Cyuan, et al.
Publicado: (2023)

Cytology–Based Specimen Triage for Epidermal Growth Factor Receptor Mutation Testing of Malignant Pleural Effusions in Non–Small Cell Lung Cancer
por: Chiang, Chi-Lu, et al.
Publicado: (2022)

Compte rendu du briefing 10 Fev. 86
por: Rosset, G
Publicado: (1986)

Variability of FEV(1) and Criterion for Acute Pulmonary Exacerbation
por: Jenkins, Bradlee A., et al.
Publicado: (2014)

Diagnosis, assessment, and phenotyping of COPD: beyond FEV(1)
por: Lange, Peter, et al.
Publicado: (2016)

Rate of Decline of FEV(1) as a Biomarker of Survival?
por: Papi, Alberto, et al.
Publicado: (2021)

Characterization of proteins regulated by interleukin-4 in 3T3-L1 adipocytes
por: Shiau, Ming-Yuh, et al.
Publicado: (2015)

Factors Associated with the Expression of ACE2 in Human Lung Tissue: Pathological Evidence from Patients with Normal FEV(1) and FEV(1)/FVC
por: Bao, Wuping, et al.
Publicado: (2021)

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
por: Wang, Jing, et al.
Publicado: (2018)

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
por: Chang, John Wen-Cheng, et al.
Publicado: (2022)

Validation and Comparison of the 7(th) Edition of the American Joint Committee on Cancer Staging System and Other Prognostic Models to Predict Relapse-Free Survival in Asian Patients with Parotid Cancer
por: Lu, Chang-Hsien, et al.
Publicado: (2016)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

Neonatal lung-derived SSEA-1(+) cells exhibited distinct stem/progenitor characteristics and organoid developmental potential
por: Liao, Chien-Chia, et al.
Publicado: (2022)

Circulating SSEA-1(+) stem cell-mediated tissue repair in allergic airway inflammation
por: Chiu, Chiao-Juno, et al.
Publicado: (2022)

Lower FEV(1) in non-COPD, nonasthmatic subjects: association with smoking, annual decline in FEV(1), total IgE levels, and TSLP genotypes
por: Masuko, Hironori, et al.
Publicado: (2011)

Cut-off value of FEV(1)/FEV(6) to determine airflow limitation using handheld spirometry in subjects with risk of chronic obstructive pulmonary disease
por: Hwang, Yong Il, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cjbm46qk49ek48m6n0l8jphg94